CLRB 300% Price Target Faces Heavy Dilution Risk
CLRB stock analysis: 100% disease control signals major cancer breakthrough — buy or sell 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends In this deep dive, we break down Cellectar Biosciences (CLRB) and its lead targeted radiopharmaceutical candidate, iopofosine I-131, which is preparing for FDA New Drug Application (NDA) submission. With shares consolidating near $2.70 against a probability-weighted price target of $19.03, the key question for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.